Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0020-708x(76)90142-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide.
Front Chem
October 2023
Center for Radiopharmaceutical Sciences (CRS), Paul Scherrer Institute, Villigen-PSI, Switzerland.
Targeted Radionuclide Therapy is used for the treatment of tumors in nuclear medicine, while sparing healthy tissues. Its application to cancer treatment is expanding. In particular, Auger-electron emitters potentially exhibit high efficacy in treating either small metastases or single tumor cells due to their short range in tissue.
View Article and Find Full Text PDFEfficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS.
Front Med (Lausanne)
October 2021
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland.
Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy ("theragnostics") in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of Tm in appropriate activities and quality. We report herein on the production of radionuclidically pure Tm from proton-irradiated natural erbium oxide targets at a cyclotron and subsequent ion beam mass separation at the CERN-MEDICIS facility, with a particular focus on the process efficiency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!